LGALS1 and type 1 diabetes mellitus: In autoimmune-prone nonobese diabetic (NOD) mice, treatment with GAL-1 reduces the amount of Th1 cells, increases the numbers of T-cells producing IL-4, IL-5, or IL-10 in response to islet antigens, and prevents the onset of hyperglycemia at both early and subclinical stages of T1D [26].